|
Post by agedhippie on Oct 7, 2017 15:04:31 GMT -5
This is why I keep banging on about the need for another trial. The biggest issue with the non-inferior trial data is that Afrezza underperformed the RAA alternative. If you show the data to an endo they will say that Afrezza has a lower hypo rate because it was underdosed. From what we know now the real issue is probably that they didn't do second doses at meal time. UNtil we can rerun the trial with the new dosing approach we will get beaten up by the existing trial data and that is not going to change. New trials now! As for settling for higher levels - most of the reason for that is eating and drinking between meals and not bolusing. There is no way I am going to bolus for all my snacks during the day, life is too short. However it adds up - 12oz latte is 50pts, bag of chips is 75pts, dried pineapple ring (a particular favorite) 40pt, and so on. People tend to have their own threshold for the point at which they will bolus, mine is 30g of carbs, and below that level they let it go and gets correct at the next meal bolus. In the interval you are running high - everyone knows it, but most people just ignore it. In the real world that is what kills time in range, most people don't want to devote the necessary effort to tight control (me amongst them). You could write an article for SA but it has to be framed from an investment view point and not medical or they will just reject it. Surely the active pediatric trials will have this dealt with No because they require less insulin and are far more insulin sensitive. Hormonal changes and growth can have some weird effects as well.
|
|
|
Post by peppy on Oct 7, 2017 15:05:52 GMT -5
once the money comes in trial away. earth to human beings with eyeballs. Insurance. The horse that had to be lead to water is wallstreet. It looks like wallstreet has decided there is money to be made on afrezza and they intend to ride it all the way up.
you can lead a horse to water, but you can not make him drink. that is a reversal.
|
|
|
Post by careful2invest on Oct 7, 2017 15:28:59 GMT -5
After reading how the article was titled, I just went straight to the comment section. I basically quit commenting bc my comments (infused with actual facts) were often never posted.
The bottom line is Afrezza actually works better than ANY OTHER mealtime insulin. The Pk/ graph comparing it to current injectable mealtime insulin, combined with the latest graph comparing Afrezza to Fiasp tells the story. The results of these two studies need to be in the hands of all GP's and Endo's and insurance companies, and somehow in the hands of every PWD for them to improve their lives. I believe that we will make it there, just not as fast as I would have initially hoped. GO MNKD! THE SKY IS THE LIMIT!
|
|
|
Post by xoxoxoxo on Oct 7, 2017 15:40:29 GMT -5
You'd think all these writers who continually bash MNKD would be focusing on what used to be the biggest problem... CANCER!
Oh wait, that hasn't been an issue at all in the years Afrezza has been on the market. The best they can do is talk about non-existant efficacy issues.
|
|
|
Post by peppy on Oct 7, 2017 16:22:56 GMT -5
Surely the active pediatric trials will have this dealt with No because they require less insulin and are far more insulin sensitive. Hormonal changes and growth can have some weird effects as well.The last time I checked, the chief job of children and adolescents was to grow. With Afrezza they can eat. Eat to life. just my two cents.
|
|
|
Post by peppy on Oct 7, 2017 18:22:24 GMT -5
I can feel the intensity growing. seeking alpha had better jump on mnkd, or it came rename its self, "missed alpha."
|
|
|
Post by sportsrancho on Oct 7, 2017 18:30:19 GMT -5
I can feel the intensity growing. seeking alpha had better jump on mnkd, or it came rename its self, "missed alpha." LMAO!
|
|
|
Post by hammer on Oct 7, 2017 21:41:20 GMT -5
I posted a few comments about this article since the author misrepresents, misinforms, or misinterprets data. One of my post was removed simply because I pointed out that he has authored a total of 79 articles on stocks and 39 of them or 50% of them have been on Afrezza and 100% have been negative. It was removed since it was a "blanket dismissal". Really, I thought it more of a factual representation of the authors credibility.
|
|
|
Post by straightly on Oct 8, 2017 0:22:11 GMT -5
No because they require less insulin and are far more insulin sensitive. Hormonal changes and growth can have some weird effects as well. The last time I checked, the chief job of children and adolescents was to grow. With Afrezza they can eat. Eat to life. just my two cents.
"With Afrezza they can eat. Eat to life." WOW! Peppy, you surprised me with your fundamental acumen also. This is an wonderful point. If Afrezza can free up a kid to a piece of pizza or a big mac, MNKD should be proud.
|
|
|
Post by sportsrancho on Oct 8, 2017 6:12:09 GMT -5
As is why kids love Afrezza!!
|
|
|
Post by sayhey24 on Oct 8, 2017 8:23:33 GMT -5
I like articles like Osborne and Feraldi and in the old days Adam F. and his comments. Debating afrezza with them is sometimes too easy but its for entertainment purposes only.
As I have told Osborne don't mess with MNKD because in many ways its like Apple was in the early 80's and has a cult following. Now Mike C. just needs to close one of the international deals to blow Osborne's analysis up.
As far as Feraldi, he not only does not understand the difference between analogs, pancreatic insulin and afrezza, he could not even read the afrezza label correctly.
|
|
|
Post by sayhey24 on Oct 8, 2017 8:30:37 GMT -5
Surely the active pediatric trials will have this dealt with No because they require less insulin and are far more insulin sensitive. Hormonal changes and growth can have some weird effects as well. Aged - based on table 4 are you still claiming non-inferiority for speed of action? Every here knows if you get the PWD back to baseline asap after a meal, A1c is only a viable measurement for a basal insulin. It should never ever again be used for evaluating any mealtime insulin.
|
|
|
Post by agedhippie on Oct 8, 2017 8:42:42 GMT -5
No because they require less insulin and are far more insulin sensitive. Hormonal changes and growth can have some weird effects as well. Aged - based on table 4 are you still claiming non-inferiority for speed of action? Every here knows if you get the PWD back to baseline asap after a meal, A1c is only a viable measurement for a basal insulin. It should never ever again be used for evaluating any mealtime insulin. I am not sure what you are saying. Are you saying that I have been saying that Afrezza has a slower action? In which case you need to reread the section on comparing Afrezza to IV delivered insulin.
|
|
|
Post by sayhey24 on Oct 8, 2017 8:55:52 GMT -5
I have no idea what you are saying. You still seem to conflating meal times with fasting periods and you still want to talk about A1c. A1c is an average like MPH. I don't want to drive 40 mph on a 70mph highway.
The goal of the pancreas and any mealtime insulin is to get you back to baseline asap. Bernstein says thats 83 in about 2 hours. Hands down afrezza wins the battle.
|
|
|
Post by agedhippie on Oct 8, 2017 10:22:50 GMT -5
I have no idea what you are saying. You still seem to conflating meal times with fasting periods and you still want to talk about A1c. A1c is an average like MPH. I don't want to drive 40 mph on a 70mph highway. The goal of the pancreas and any mealtime insulin is to get you back to baseline asap. Bernstein says thats 83 in about 2 hours. Hands down afrezza wins the battle. Yes, I agree, that's why I am puzzled about what you are accusing me of. The problem is that the medical profession broadly doesn't agree.
|
|